2021 - Cancer Currents Blog
-
FDA’s recent approval of relugolix (Orgovyx) is expected to affect the treatment of men with advanced prostate cancer. A large clinical trial showed that relugolix was more effective at reducing testosterone levels than another common treatment.
-
Obesity changed the relationship between cancer cells and nearby immune cells in ways that helped tumors survive and grow, a study in mice showed. But altering tumor cell metabolism helped immune cells once again recognize and infiltrate tumors.
-
Cancer cells that are leftover after treatment can go into a “dormant” state for years. A new study in mice suggests that stress hormones may trigger a chain reaction that wakes up dormant cancer cells, causing tumors to form again.
-
With the Cancer Moonshot having reached its midway point, NCI Director Dr. Ned Sharpless and Deputy Director Dr. Dinah Singer provide a report on the progress to date and future directions for this ambitious initiative to accelerate progress against cancer.
-
The drug abemaciclib (Verzenio) may be a new treatment option for people with the most common type of breast cancer, with new study findings suggesting that it can reduce the risk of the cancer returning.